CXCR7 expression in esophageal cancer

Journal of Translational Medicine

Maximilian Bockhorn²  Jakob R Izbicki²  Klaus Pantel³  Katharina von Loga¹  Florian Gebauer²  Hilke Zander²  Michael Tachezy² 

[1] Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany;Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany

关键词: Esophageal cancer;    Esophagus;    CXCL12;    CXCR7;    CXCR4;   

Others  :  826230
DOI  :  10.1186/1479-5876-11-238

 received in 2013-05-06, accepted in 2013-09-25,  发布年份 2013

【 摘 要 】

Background

The chemokine CXCL12 and its receptor CXCR4 play a major role in tumor invasion, proliferation and metastasis in different malignant diseases, including esophageal carcinoma, amongst others. CXCR7 was recently identified as a novel alternate receptor for CXCL12. The aim of this study was to evaluate the prognostic impact of expression of chemokine receptor CXCR7 in patients with esophageal carcinoma (EC).

Methods

Expression of CXCR7 in primary tumors, lymph nodes and distant metastases of 299 patients with EC was evaluated by immunohistochemistry on a tissue microarray and compared with clinical and histopathological data.

Results

In esophageal cancer sections, CXCR7-specific reactivity was apparent in 45% of the squamous cell carcinomas (ESCC), but only occasionally in adenocarcinomas. No correlation between CXCR4 and CXCR7 expression was evident. We correlated expression with clinical and histopathological characteristics, but could not find any association.

Conclusions

Contrary to the other known CXCL12 receptor, CXCR4, CXCR7 is expressed in ESCC only, underlining the divergent mechanisms and backgrounds of EAC and ESCC. The results of the study do not indicate a significant functional role for CXCR7 in EAC or ESCC of the esophagus. However, its variable expression in the main two main types of EC needs to be further investigated.

【 授权许可】

   
2013 Tachezy et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Yekebas EF, Schurr PG, Kaifi JT, Link BC, Kutup A, et al.: Effectiveness of radical en-bloc-esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases. J Surg Oncol 2006, 93:541-549.
• [2]Koenig AM, Prenzel KL, Bogoevski D, Yekebas EF, Bubenheim M, et al.: Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol 2009, 16:454-462.
• [3]Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, et al.: Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005, 97:1840-1847.
• [4]Hyngstrom JR, Posner MC: Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol 2010, 101:299-304.
• [5]Barnett SA, Rizk NP: Randomized clinical trials in esophageal carcinoma. Surg Oncol Clin N Am 2010, 19:59-80.
• [6]O’Reilly S, Forastiere A: New approaches to treating oesophageal cancer. BMJ 1994, 308:1249-1250.
• [7]Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, et al.: Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001, 234:360-367. discussion 368–369
• [8]Oshima T, Masuda M: Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today 2012, 42:313-327.
• [9]Wu X, Lee VC, Chevalier E, Hwang ST: Chemokine receptors as targets for cancer therapy. Curr Pharm Des 2009, 15:742-757.
• [10]Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
• [11]Lazennec G, Richmond A: Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010, 16:133-144.
• [12]Maksym RB, Tarnowski M, Grymula K, Tarnowska J, Wysoczynski M, et al.: The role of stromal-derived factor-1–CXCR7 axis in development and cancer. Eur J Pharmacol 2009, 625:31-40.
• [13]Sun X, Cheng G, Hao M, Zheng J, Zhou X, et al.: CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010, 29:709-722.
• [14]Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, et al.: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213.
• [15]Gros SJ, Kurschat N, Drenckhan A, Dohrmann T, Forberich E, et al.: Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PLoS One 2012, 7:e47287.
• [16]Gros SJ, Graeff H, Drenckhan A, Kurschat N, Blessmann M, et al.: CXCR4/SDF-1alpha-mediated chemotaxis in an in vivo model of metastatic esophageal carcinoma. In Vivo 2012, 26:711-718.
• [17]Gockel I, Schimanski CC, Heinrich C, Wehler T, Frerichs K, et al.: Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer 2006, 6:290. BioMed Central Full Text
• [18]Sasaki K, Natsugoe S, Ishigami S, Matsumoto M, Okumura H, et al.: Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancer. J Surg Oncol 2008, 97:433-438.
• [19]Wang DF, Lou N, Zeng CG, Zhang X, Chen FJ: Expression of CXCL12/CXCR4 and its correlation to prognosis in esophageal squamous cell carcinoma. Ai Zheng 2009, 28:154-158.
• [20]Zhang L, Ye SB, Ma G, Tang XF, Chen SP, et al.: The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma. J Transl Med 2013, 11:60. BioMed Central Full Text
• [21]Drenckhan A, Kurschat N, Dohrmann T, Raabe N, Koenig AM, et al.: Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J Surg Res 2013, 182:250-256.
• [22]Vashist YK, Effenberger KE, Vettorazzi E, Riethdorf S, Yekebas EF, et al.: Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer. Ann Surg 2012, 255:1105-1112.
• [23]Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, et al.: Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007, 20:120-129.
• [24]Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, et al.: ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer 2012, 131:396-405.
• [25]Simon R, Mirlacher M, Sauter G: Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 2010, 664:113-126.
• [26]Sanchez-Martin L, Sanchez-Mateos P, Cabanas C: CXCR7 impact on CXCL12 biology and disease. Trends Mol Med 2013, 19:12-22.
• [27]Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, et al.: CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007, 104:15735-15740.
• [28]Imai H, Sunaga N, Shimizu Y, Kakegawa S, Shimizu K, et al.: Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. Int J Immunopathol Pharmacol 2010, 23:153-164.
• [29]Torres C, Turner JR, Wang HH, Richards W, Sugarbaker D, et al.: Pathologic prognostic factors in Barrett’s associated adenocarcinoma: a follow-up study of 96 patients. Cancer 1999, 85:520-528.
• [30]Theunissen PH, Borchard F, Poortvliet DC: Histopathological evaluation of oesophageal carcinoma: the significance of venous invasion. Br J Surg 1991, 78:930-932.
• [31]International Union Against Cancer: Oesophagus including Oesophagogastric Junction. In Classification of Malignant Tumours. 7th edition. Edited by Sobin LH, Gospodarowicz MK, Wittekind C. New York, NY: Wiley Blackwell; 2009:66-72.
• [32]Wang J, Shiozawa Y, Wang Y, Jung Y, Pienta KJ, et al.: The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008, 283:4283-4294.
• [33]Iwakiri S, Mino N, Takahashi T, Sonobe M, Nagai S, et al.: Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 2009, 115:2580-2593.